Alcresta Therapeutics

Focus: Alcresta Therapeutics is a biotech company focused on digestive enzyme devices, specifically developing immobilized lipase for exocrine pancreatic insufficiency. The company operates as a pre-revenue or early-stage biotech with minimal public disclosure of scale or market position.

Unknown

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Open Jobs

About Alcresta Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Alcresta Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RELiZORB

Exocrine Pancreatic Insufficiency

N/A

Clinical Trials (1)

NCT02598128Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

N/A

Help build intelligence for Alcresta Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Single focused pipeline program in Phase 3 with 5 active trials indicates disciplined R&D strategy around a clear unmet need in pancreatic insufficiency
Early-stage biotech environment offers hands-on roles with potential for significant career acceleration if immobilized lipase achieves regulatory success
Massachusetts biotech hub location provides access to pharma talent networks and potential acquisition targets

Watch Out For

Only 3 active job openings and undisclosed employee count suggest very small team with limited growth trajectory and career mobility within company
No disclosed revenue, funding, or financials raise serious questions about runway, sustainability, and ability to retain talent through Phase 3 completion
Zero published research and single-asset pipeline indicate high binary risk—failure of immobilized lipase program threatens company viability and job security

Generated by Claude from Alcresta Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RELiZORB™

Multi Organ Failure

N/A

Clinical Trials (1)

NCT05710315Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure

N/A

Relizorb

Short Bowel Syndrome

N/A

Clinical Trials (1)

NCT03530852A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

N/A